LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway

BACKGROUND: Oral squamous cell carcinoma (OSCC) is a common oral cancer. The current study aims to elucidate the potential roles of long noncoding RNA (lncRNA) LHFPL3-AS1 in OSCC development. METHODS: Gene expression was measured by qRT-PCR in tumor tissues and cell lines. Loss-of-function assays we...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiandong, Xu, Xiaohu, Zhang, Dandan, Lv, Han, Lei, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020056/
https://www.ncbi.nlm.nih.gov/pubmed/33833527
http://dx.doi.org/10.2147/OTT.S298679
_version_ 1783674508178096128
author Li, Jiandong
Xu, Xiaohu
Zhang, Dandan
Lv, Han
Lei, Xin
author_facet Li, Jiandong
Xu, Xiaohu
Zhang, Dandan
Lv, Han
Lei, Xin
author_sort Li, Jiandong
collection PubMed
description BACKGROUND: Oral squamous cell carcinoma (OSCC) is a common oral cancer. The current study aims to elucidate the potential roles of long noncoding RNA (lncRNA) LHFPL3-AS1 in OSCC development. METHODS: Gene expression was measured by qRT-PCR in tumor tissues and cell lines. Loss-of-function assays were performed to analyze the effects of LHFPL3-AS1 on malignant behaviors. Bioinformatics analysis was conducted to explore the downstream signaling pathway of LHFPL3-AS1 in OSCC. RESULTS: LHFPL3-AS1 was highly expressed in OSCC tissues and cell lines. LHFPL3-AS1 was upregulated in cisplatin-resistant tumor cell lines. LHFPL3-AS1 level was correlated with survival rate. LHFPL3-AS1 knockdown suppressed OSCC proliferation, migration and invasion. LHFPL3-AS1 downregulation reduced cisplatin resistance of OSCC cells. LHFPL3-AS1 was the competing endogenous RNA (ceRNA) for miR-194-5p to enhance CHSY1 expression. CONCLUSION: LHFPL3-AS1/miR-362-5p/CHSY1 signaling pathway plays essential roles in regulating OSCC development and cisplatin resistance.
format Online
Article
Text
id pubmed-8020056
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80200562021-04-07 LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway Li, Jiandong Xu, Xiaohu Zhang, Dandan Lv, Han Lei, Xin Onco Targets Ther Original Research BACKGROUND: Oral squamous cell carcinoma (OSCC) is a common oral cancer. The current study aims to elucidate the potential roles of long noncoding RNA (lncRNA) LHFPL3-AS1 in OSCC development. METHODS: Gene expression was measured by qRT-PCR in tumor tissues and cell lines. Loss-of-function assays were performed to analyze the effects of LHFPL3-AS1 on malignant behaviors. Bioinformatics analysis was conducted to explore the downstream signaling pathway of LHFPL3-AS1 in OSCC. RESULTS: LHFPL3-AS1 was highly expressed in OSCC tissues and cell lines. LHFPL3-AS1 was upregulated in cisplatin-resistant tumor cell lines. LHFPL3-AS1 level was correlated with survival rate. LHFPL3-AS1 knockdown suppressed OSCC proliferation, migration and invasion. LHFPL3-AS1 downregulation reduced cisplatin resistance of OSCC cells. LHFPL3-AS1 was the competing endogenous RNA (ceRNA) for miR-194-5p to enhance CHSY1 expression. CONCLUSION: LHFPL3-AS1/miR-362-5p/CHSY1 signaling pathway plays essential roles in regulating OSCC development and cisplatin resistance. Dove 2021-03-31 /pmc/articles/PMC8020056/ /pubmed/33833527 http://dx.doi.org/10.2147/OTT.S298679 Text en © 2021 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Jiandong
Xu, Xiaohu
Zhang, Dandan
Lv, Han
Lei, Xin
LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway
title LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway
title_full LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway
title_fullStr LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway
title_full_unstemmed LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway
title_short LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway
title_sort lncrna lhfpl3-as1 promotes oral squamous cell carcinoma growth and cisplatin resistance through targeting mir-362-5p/chsy1 pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020056/
https://www.ncbi.nlm.nih.gov/pubmed/33833527
http://dx.doi.org/10.2147/OTT.S298679
work_keys_str_mv AT lijiandong lncrnalhfpl3as1promotesoralsquamouscellcarcinomagrowthandcisplatinresistancethroughtargetingmir3625pchsy1pathway
AT xuxiaohu lncrnalhfpl3as1promotesoralsquamouscellcarcinomagrowthandcisplatinresistancethroughtargetingmir3625pchsy1pathway
AT zhangdandan lncrnalhfpl3as1promotesoralsquamouscellcarcinomagrowthandcisplatinresistancethroughtargetingmir3625pchsy1pathway
AT lvhan lncrnalhfpl3as1promotesoralsquamouscellcarcinomagrowthandcisplatinresistancethroughtargetingmir3625pchsy1pathway
AT leixin lncrnalhfpl3as1promotesoralsquamouscellcarcinomagrowthandcisplatinresistancethroughtargetingmir3625pchsy1pathway

Ejemplares similares